Samsung Bioepis has joined with Takeda to develop multiple novel biologic therapies, including the collaboration’s first therapeutic candidate, TAK-671 for severe acute pancreatitis, according to a press release.
“Takeda’s extensive knowledge and expertise in drug development makes the company an ideal partner for us as we open a new chapter at Samsung Bioepis,” Christopher Hansung Ko, president and CEO of Samsung Bioepis, said in the release. “Together with Takeda, we look forward to realizing this vision by accelerating the development of effective therapies for patients who are currently without a viable treatment option.”
Takeda’s head of the center for external innovation, Daniel Curran, MD, also commented saying, “At Takeda, we think differently — and creatively — about what makes a partnership successful and look to build on our strengths by collaborating with partners who have complementary expertise.”
Additional terms of the collaboration have not been disclosed yet.